智通财经APP讯，博安生物(06955)发布截至2024年12月31日止年度业绩，该集团取得收入人民币7.26亿元(单位下同)，同比增加17.5%;母公司拥有人应占溢利7318.9万元，去年同期则取得亏损1.19亿元;每股盈利0.14元。
于报告期间，凭藉积极的营销策略及高效的销售执行能力，本集团已建立一支专业的商业化团队，借此迅速在国内市场站稳脚跟，为本公司后续转型打下了坚实的基础。随着三款产品的商业化，本集团于报告期间的收入高速增长。
公告称，收入增加主要是由于博优诺®(BA1101)及博优倍®(BA6101)在中国的销售增长以及许可收入增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.